GENE ONLINE|News &
Opinion
Blog

2022-08-11| Trials & Approvals

Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease

by Max Heirich
Share To

On August 11, Graphite Bio announced that they dosed their first patient with GPH101. GPH101, otherwise referred to as nula-cel (nulabeglogene autogedtemcel), is a gene repair treatment for sickle cell disease. The therapy is currently under analysis in the Phase ½ CEDAR clinical trial. Gene Repair of Sickle Cell Disease has the potential to nullify need for hemoglobin polymerization inhibitors.

Related Article: CRISPR Biotech Editas Obtains FDA Rare Pediatric Disease Label

The Current Treatments of Sickle Cell Disease

Sickle cell disease is a devastating blood disorder wherein a patient’s blood cells change into a sickle shape. As a result, the sickle blood cells lack a healthy cell’s capacity for carrying oxygen—that lack of oxygen results in low levels throughout the body. In addition, patients experience chronic symptoms like joint pain, dizziness, inflammation, and shortness of breath. 

Sickle cell disease is a chronic condition caused when a person inherits two defective hemoglobin genes from each parent. When someone inherits only one sickle cell gene, known as hemoglobin S, that individual is generally healthy. However, when two hemoglobin S genes, or one and another faulty hemoglobin gene, are inherited, that person develops sickle cell disease. As a result, the available medicines only treat the symptoms of sickle cell disease. 

An example of one of these treatments is Droxia (hydroxyurea). Produced by Bristol Myers Squibb, Droxia inhibits an enzyme known as ribonucleotide reductase, resulting in a reduced chance of sickle cells forming. 

However, nula-cel could be a treatment that repairs the broken gene causing sickle cell formation in the first place. 

Repairing the Cause of SCD

Nula-cel works by directly editing the gene mutation causing sickle cell disease with CRISPR technology. As a result of this edit, hemoglobin would begin to produce healthily shaped cells rather than sickled ones. Currently, the Phase ½ CEDAR Trial is evaluating the safety, preliminary efficacy, and pharmacodynamics of nula-cel. Fifteen participants affected by severe sickle cell disease are the subjects of the trial.

Josh Lehrer, M.D., M.Phil., chief executive officer of Graphite Bio, said, “We continue to make tremendous progress with the development of nula-cel, which in preclinical studies successfully corrected the sickle cell disease mutation, directly reducing sickle hemoglobin and restoring healthy adult hemoglobin to potentially curative levels.”

Should the trial results prove fruitful, Graphite Bio might have a contender for sickle hemoglobin polymerization inhibitors like Droxia and Global Blood Therapeutics’ Oxbryta. 

Graphite Bio expects the CEDAR trial to conclude its findings of nula-cel in May 2026. 

Related Article: Pfizer Acquires Global Blood Therapeutics and its sickle cell disease expertise for $5.4 billion

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
US BIO 2025 to Unite 20,000+ Global Biotech Leaders in Boston for Innovation, Policy, and Investment Collaboration
2025-06-12
Dutch Government Collapses as Wilders’ Exit Puts Biotech Sector at Risk
2025-06-04
R&D
Neurodegenerative and Metabolic Disease Challenges and Solutions at ASGCT 2025
2025-05-15
LATEST
Sichuan University Study Finds Nighttime Blood Pressure Medication Improves Nocturnal Control
2025-07-14
FDA Approves Expanded Use of Bayer’s Kerendia for Treating Heart Failure
2025-07-14
AstraZeneca Completes Phase 3 Trial for Hypertension Drug Acquired in $1.3 Billion CinCor Deal
2025-07-14
CMS Proposes Medicare Coverage for Renal Denervation to Address Uncontrolled Hypertension
2025-07-14
Novartis Highlights Creativity as Core to Elevating US Pharma Marketing Strategies
2025-07-14
FDA Begins Reauthorization Process for GDUFA IV with Public Meeting
2025-07-14
FDA Approves InspireMD’s CGuard Prime as First Mesh-Covered Carotid Stent with CMS Coverage
2025-07-14
EVENT
2025-07-23
BIO Asia–Taiwan 2025
Taipei, Taiwan
2025-08-08
HEALTHY AGEING TECH SHOW
Taipei, Taiwan
2025-08-09
MEDINFO 2025
Taipei, Taiwan
2025-09-03
BIO ASIA PACIFIC 2025
Bangkok, Thailand
2025-09-10
BIOHK 2025
Hong Kong
2025-10-01
Medical Japan 2025
Osaka, Japan
Scroll to Top